Mesoblast Ltd
ASX:MSB
Intrinsic Value
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. [ Read More ]
The intrinsic value of one MSB stock under the Base Case scenario is 2.642 AUD. Compared to the current market price of 0.915 AUD, Mesoblast Ltd is Undervalued by 65%.
Valuation Backtest
Mesoblast Ltd
Run backtest to discover the historical profit from buying and selling MSB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Mesoblast Ltd
Current Assets | 85.2m |
Cash & Short-Term Investments | 77.1m |
Receivables | 4m |
Other Current Assets | 4m |
Non-Current Assets | 585.1m |
Long-Term Investments | 826k |
PP&E | 5.5m |
Intangibles | 576.6m |
Other Non-Current Assets | 2.2m |
Current Liabilities | 31.4m |
Accounts Payable | 10.8m |
Accrued Liabilities | 4m |
Other Current Liabilities | 16.6m |
Non-Current Liabilities | 130.2m |
Long-Term Debt | 110.6m |
Other Non-Current Liabilities | 19.6m |
Earnings Waterfall
Mesoblast Ltd
Revenue
|
7.5m
USD
|
Cost of Revenue
|
-21.7m
USD
|
Gross Profit
|
-14.3m
USD
|
Operating Expenses
|
-41.1m
USD
|
Operating Income
|
-55.3m
USD
|
Other Expenses
|
-17.7m
USD
|
Net Income
|
-73.1m
USD
|
Free Cash Flow Analysis
Mesoblast Ltd
MSB Profitability Score
Profitability Due Diligence
Mesoblast Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Mesoblast Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
MSB Solvency Score
Solvency Due Diligence
Mesoblast Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Mesoblast Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MSB Price Targets Summary
Mesoblast Ltd
According to Wall Street analysts, the average 1-year price target for MSB is 1.346 AUD with a low forecast of 0.555 AUD and a high forecast of 2.741 AUD.
Shareholder Return
MSB Price
Mesoblast Ltd
Average Annual Return | -9% |
Standard Deviation of Annual Returns | 35.05% |
Max Drawdown | -95% |
Market Capitalization | 1B AUD |
Shares Outstanding | 1 140 031 371 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 83 full-time employees. The company went IPO on 2004-12-16. The firm is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.
Contact
IPO
Employees
Officers
The intrinsic value of one MSB stock under the Base Case scenario is 2.642 AUD.
Compared to the current market price of 0.915 AUD, Mesoblast Ltd is Undervalued by 65%.